In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finch Therapeutics Group Inc.

finchtherapeutics.com

Latest From Finch Therapeutics Group Inc.

Microbiome Offers Rich Pickings As Takeda Becomes Enterome's Second Big Pharma Crohn's Partner

Takeda's $50m+ deal for Enterome's EB8018 is based on a separate platform from that being used under the French company's collaboration with Johnson & Johnson.

Inflammation Gastrointestinal

Venture Funding Deals: MedImmune Spinout Viela Lands $250m Series A

China's JW Therapeutics nets $90m for cancer cell therapy, including backing from biotechs Celgene and WuXi. Meanwhile, Foghorn sounds out a $50m A round for its gene trafficking technology applications.

Deals Financing

How Intract Is Helping Shape Microbiome-Based Therapies

Bill Lindsay, CEO of University College London spin-out Intract Pharma, tells Scrip in an interview how the firm’s novel technologies are expected to play a key role in the effective delivery of microbiome-based therapies.
Commercial Innovation

Finance Watch: VC Interest Lags At Early Stage – 'Hogwash' Or Evidence-Based?

Venture Capital Edition: A VC investor at a recent conference said it's "hogwash" that venture capitalists aren't interested in funding early-stage biopharma, but the trend toward large financings – such as the $220m raised to date by Rubius – and 2017 investment data suggest otherwise.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Infectious & Viral Diseases
  • Alias(es)
  • Finch Therapeutics Inc.
  • NextBiome Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Finch Therapeutics Group Inc.
  • Senior Management
  • Mark Smith, PhD, CEO
    Gregory Perry, CFO
    Ulrich Thienel, MD, PhD, CMO
  • Contact Info
  • Finch Therapeutics Group Inc.
    Phone: (617) 229-6499
    200 Inner Belt Rd., Ste. 400
    Somerville, MA 02143
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register